Literature DB >> 30759384

Pseudovirus rVSVΔG-ZEBOV-GP Infects Neurons in Retina and CNS, Causing Apoptosis and Neurodegeneration in Neonatal Mice.

Ian L McWilliams1, Jennifer L Kielczewski2, Derek D C Ireland1, Jacob S Sykes1, Aaron P Lewkowicz1, Krishnamurthy Konduru3, Biying C Xu2, Chi-Chao Chan2, Rachel R Caspi2, Mohanraj Manangeeswaran4, Daniela Verthelyi5.   

Abstract

Zaire Ebola virus (ZEBOV) survivors experience visual and CNS sequelae that suggests the ZEBOV glycoprotein can mediate neurotropism. Replication-competent rVSVΔG-ZEBOV-GP vaccine candidate is generally well tolerated; however, its potential neurotropism requires careful study. Here, we show that a single inoculation of rVSVΔG-ZEBOV-GP virus in neonatal C57BL/6 mice results in transient viremia, neurological symptoms, high viral titers in eyes and brains, and death. rVSVΔG-ZEBOV-GP infects the inner layers of the retina, causing severe retinitis. In the cerebellum, rVSVΔG-ZEBOV-GP infects neurons in the granular and Purkinje layers, resulting in progressive foci of apoptosis and neurodegeneration. The susceptibility to infection is not due to impaired type I IFN responses, although MDA5-/-, IFNβ-/-, and IFNAR1-/- mice have accelerated mortality. However, boosting interferon levels by co-administering poly(I:C) reduces viral titers in CNS and improves survival. Although these data should not be directly extrapolated to humans, they challenge the hypothesis that VSV-based vaccines are non-neurotropic. Published by Elsevier Inc.

Entities:  

Keywords:  Ebola glycoprotein; Ebola vaccine; Ebola virus; VSV; VSV vaccine; ebolavirus; filovirus; innate immunity; neurotropism; neurovirulence; pseudotyped virus

Mesh:

Year:  2019        PMID: 30759384      PMCID: PMC6748882          DOI: 10.1016/j.celrep.2019.01.069

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  41 in total

1.  Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.

Authors:  Selidji T Agnandji; Angela Huttner; Madeleine E Zinser; Patricia Njuguna; Christine Dahlke; José F Fernandes; Sabine Yerly; Julie-Anne Dayer; Verena Kraehling; Rahel Kasonta; Akim A Adegnika; Marcus Altfeld; Floriane Auderset; Emmanuel B Bache; Nadine Biedenkopf; Saskia Borregaard; Jessica S Brosnahan; Rebekah Burrow; Christophe Combescure; Jules Desmeules; Markus Eickmann; Sarah K Fehling; Axel Finckh; Ana Rita Goncalves; Martin P Grobusch; Jay Hooper; Alen Jambrecina; Anita L Kabwende; Gürkan Kaya; Domtila Kimani; Bertrand Lell; Barbara Lemaître; Ansgar W Lohse; Marguerite Massinga-Loembe; Alain Matthey; Benjamin Mordmüller; Anne Nolting; Caroline Ogwang; Michael Ramharter; Jonas Schmidt-Chanasit; Stefan Schmiedel; Peter Silvera; Felix R Stahl; Henry M Staines; Thomas Strecker; Hans C Stubbe; Benjamin Tsofa; Sherif Zaki; Patricia Fast; Vasee Moorthy; Laurent Kaiser; Sanjeev Krishna; Stephan Becker; Marie-Paule Kieny; Philip Bejon; Peter G Kremsner; Marylyn M Addo; Claire-Anne Siegrist
Journal:  N Engl J Med       Date:  2015-04-01       Impact factor: 91.245

2.  Severe Ebola Virus Infection With Encephalopathy: Evidence for Direct Virus Involvement.

Authors:  Emmanuel Sagui; Frédéric Janvier; Sylvain Baize; Vincent Foissaud; Fassou Koulibaly; Hélène Savini; Nancy Maugey; Marc Aletti; Hervé Granier; Thierry Carmoi
Journal:  Clin Infect Dis       Date:  2015-07-21       Impact factor: 9.079

3.  Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain.

Authors:  Anthony N van den Pol; Guochao Mao; Anasuya Chattopadhyay; John K Rose; John N Davis
Journal:  J Virol       Date:  2017-02-28       Impact factor: 5.103

4.  Understanding How Zika Virus Enters and Infects Neural Target Cells.

Authors:  Jonathan J Miner; Michael S Diamond
Journal:  Cell Stem Cell       Date:  2016-05-05       Impact factor: 24.633

5.  Viral infection and neural stem/progenitor cell's fate: implications in brain development and neurological disorders.

Authors:  Sulagna Das; Anirban Basu
Journal:  Neurochem Int       Date:  2011-02-24       Impact factor: 3.921

Review 6.  Ebola virus vaccines: Where do we stand?

Authors:  Vincent Pavot
Journal:  Clin Immunol       Date:  2016-10-28       Impact factor: 3.969

7.  Persistence of Ebola Virus in Ocular Fluid during Convalescence.

Authors:  Jay B Varkey; Jessica G Shantha; Ian Crozier; Colleen S Kraft; G Marshall Lyon; Aneesh K Mehta; Gokul Kumar; Justine R Smith; Markus H Kainulainen; Shannon Whitmer; Ute Ströher; Timothy M Uyeki; Bruce S Ribner; Steven Yeh
Journal:  N Engl J Med       Date:  2015-05-07       Impact factor: 91.245

Review 8.  Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead.

Authors:  Everardo González-González; Mario Moisés Alvarez; Alan Roberto Márquez-Ipiña; Grissel Trujillo-de Santiago; Luis Mario Rodríguez-Martínez; Nasim Annabi; Ali Khademhosseini
Journal:  Crit Rev Biotechnol       Date:  2015-11-26       Impact factor: 8.429

9.  Post-Ebola Syndrome, Sierra Leone.

Authors:  Janet T Scott; Foday R Sesay; Thomas A Massaquoi; Baimba R Idriss; Foday Sahr; Malcolm G Semple
Journal:  Emerg Infect Dis       Date:  2016-04       Impact factor: 6.883

Review 10.  The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials.

Authors:  Ellen Suder; Wakako Furuyama; Heinz Feldmann; Andrea Marzi; Emmie de Wit
Journal:  Hum Vaccin Immunother       Date:  2018-06-18       Impact factor: 3.452

View more
  13 in total

1.  Peripheral Neuronopathy Associated With Ebola Virus Infection in Rhesus Macaques: A Possible Cause of Neurological Signs and Symptoms in Human Ebola Patients.

Authors:  David X Liu; Donna L Perry; Timothy K Cooper; Louis M Huzella; Randy J Hart; Amanda M W Hischak; John G Bernbaum; Lisa E Hensley; Richard S Bennett
Journal:  J Infect Dis       Date:  2020-10-13       Impact factor: 5.226

2.  Multilamellar Vaccine Particle Elicits Potent Immune Activation with Protein Antigens and Protects Mice against Ebola Virus Infection.

Authors:  Yuchen Fan; Sabrina M Stronsky; Yao Xu; Jesse T Steffens; Sean A van Tongeren; Amanda Erwin; Christopher L Cooper; James J Moon
Journal:  ACS Nano       Date:  2019-09-12       Impact factor: 15.881

3.  Longitudinal in vivo imaging of acute neuropathology in a monkey model of Ebola virus infection.

Authors:  William Schreiber-Stainthorp; Jeffrey Solomon; Ji Hyun Lee; Marcelo Castro; Swati Shah; Neysha Martinez-Orengo; Rebecca Reeder; Dragan Maric; Robin Gross; Jing Qin; Katie R Hagen; Reed F Johnson; Dima A Hammoud
Journal:  Nat Commun       Date:  2021-05-17       Impact factor: 14.919

4.  Single-component multilayered self-assembling nanoparticles presenting rationally designed glycoprotein trimers as Ebola virus vaccines.

Authors:  Linling He; Anshul Chaudhary; Xiaohe Lin; Cindy Sou; Tanwee Alkutkar; Sonu Kumar; Timothy Ngo; Ezra Kosviner; Gabriel Ozorowski; Robyn L Stanfield; Andrew B Ward; Ian A Wilson; Jiang Zhu
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

5.  CpG Oligonucleotides Protect Mice From Alphavirus Encephalitis: Role of NK Cells, Interferons, and TNF.

Authors:  Mohanraj Manangeeswaran; Aaron P Lewkowicz; Tomer Israely; Derek D C Ireland; Daniela Verthelyi
Journal:  Front Immunol       Date:  2020-02-18       Impact factor: 7.561

6.  Generation of SARS-CoV-2 Spike Pseudotyped Virus for Viral Entry and Neutralization Assays: A 1-Week Protocol.

Authors:  Jose Manuel Condor Capcha; Guerline Lambert; Derek M Dykxhoorn; Alessandro G Salerno; Joshua M Hare; Michael A Whitt; Savita Pahwa; Dushyantha T Jayaweera; Lina A Shehadeh
Journal:  Front Cardiovasc Med       Date:  2021-01-15

Review 7.  Ebola virus disease.

Authors:  Shevin T Jacob; Ian Crozier; William A Fischer; Angela Hewlett; Colleen S Kraft; Marc-Antoine de La Vega; Moses J Soka; Victoria Wahl; Anthony Griffiths; Laura Bollinger; Jens H Kuhn
Journal:  Nat Rev Dis Primers       Date:  2020-02-20       Impact factor: 52.329

Review 8.  Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2.

Authors:  Aline Baldo; Amaya Leunda; Nicolas Willemarck; Katia Pauwels
Journal:  Vaccines (Basel)       Date:  2021-05-03

9.  Vesiculopolins, a New Class of Anti-Vesiculoviral Compounds, Inhibit Transcription Initiation of Vesiculoviruses.

Authors:  Minako Ogino; Yuriy Fedorov; Drew J Adams; Kazuma Okada; Naoto Ito; Makoto Sugiyama; Tomoaki Ogino
Journal:  Viruses       Date:  2019-09-14       Impact factor: 5.048

10.  A Surrogate Animal Model for Screening of Ebola and Marburg Glycoprotein-Targeting Drugs Using Pseudotyped Vesicular Stomatitis Viruses.

Authors:  Takeshi Saito; Junki Maruyama; Noriyo Nagata; Mao Isono; Kosuke Okuya; Yoshihiro Takadate; Yurie Kida; Hiroko Miyamoto; Akina Mori-Kajihara; Takanari Hattori; Wakako Furuyama; Shinya Ogawa; Shigeru Iida; Ayato Takada
Journal:  Viruses       Date:  2020-08-22       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.